As with any medicine, the MHRA will keep the safety and effectiveness of brensocatib under close review.
Similar Posts
Decentralised manufacture: UK Guideline on Good Manufacturing Practice (GMP)
UK guideline on GMP for decentralised manufacturing, ensuring compliance with EU GMP principles for safe, quality medicinal products.
Nirogacestat hydrobromide approved to treat desmoid tumours
As with any medicine, the MHRA will keep the safety and effectiveness of Nirogacestat hydrobromide under close review.
Class 2 Medicines Recall: Crescent Pharma Limited, Ramipril 5mg capsules, EL(26)A/11
Crescent Pharma Limited is recalling one batch of Ramipril 5 mg Capsules as a precautionary measure due to a potential error at the manufacturing site.
MHRA begins recruitment for new digital roles at Leeds hub to drive innovation and smarter regulation
New jobs to strengthen innovation, safety and smarter regulation across the UK health and life sciences sector.
Decision: Marketing authorisations Granted in 2026
Marketing authorisations Granted in 2026.
UK and Singapore launch a regulatory innovation corridor to speed up access to breakthrough health technologies
Patients in the UK and Singapore could gain faster access to cutting-edge healthcare innovations under a new partnership bringing two globally respected regulators together with one of the world’s leading biotech creators.